Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Biosciences disclosed on November 17, 2026 that it has awarded equity inducement grants to newly hired employees, in a notice issued under Nasdaq Listing Rule 5635(c)(4).

That rule allows listed companies to grant stock options or other equity awards to people joining the company without first seeking shareholder approval, provided the awards are a material inducement to accept employment and are approved by independent directors or an independent compensation committee. Companies must promptly announce such grants publicly, which is why biotechnology firms regularly issue brief statements describing them.

Inducement awards are a common recruiting tool in the life sciences sector, where companies compete for specialised scientific, clinical and commercial talent. The grants typically take the form of stock options that vest over several years, tying the value of compensation to the company’s future performance and encouraging employees to stay through key development milestones.

Annexon, based in Brisbane, California, is a clinical-stage biopharmaceutical company developing therapies that target the classical complement pathway, a part of the immune system implicated in neurological, autoimmune and ophthalmic diseases. Its programs have included candidates for Guillain-Barre syndrome and geographic atrophy, an advanced form of age-related macular degeneration. The company’s shares trade on the Nasdaq under the ticker ANNX.

 

Created by Ayen Stabel.

 

Stabel is AI and can make mistakes.

Sources:

https://www.globenewswire.com/news-release/2026/11/17/3405167/0/en/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4.html

Leave a Reply

Your email address will not be published. Required fields are marked *